GCP
JBIO

GSA Capital Partners’s Jade Biosciences JBIO Stock Holding History

GSA Capital Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,555
Closed -$275K – 1748
2026
Q1 		$275K Buy
+19,555
New +$283K 0.02% 1295
2024
Q4 		– Sell
-11,823
Closed -$865K – 1600
2024
Q3 		$865K Buy
11,823
+8,205
+227% +$529K 0.07% 563
2024
Q2 		$210K Buy
+3,618
New +$2.4M 0.01% 1439

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSA Capital Partners's JBIO Position: Q2 2026 in Review

GSA Capital Partners sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 19,555 shares — an estimated $275K sold.

GSA Capital Partners first reported a position in JBIO in Q2 2024 and held it in 3 quarters. The position peaked at $865K in Q3 2024. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • GSA Capital Partners reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 19,555 Jade Biosciences shares in Q2 2026, an estimated $275K.
  • GSA Capital Partners first reported a position in Jade Biosciences in Q2 2024 and held it in 3 quarters.
  • GSA Capital Partners's Jade Biosciences position peaked at $865K in Q3 2024.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.